

Zoetis beats Q3 earnings and revenue estimates, lifts full-year 2026 guidance, and balances pet care affordability pressures with steady livestock gains.
You can purchase shares of Zoetis (NYSE:ZTS) through any online brokerage.
Other companies in Zoetis’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Zoetis has a consensus price target of $129.74.
The stock price for Zoetis (NYSE: ZTS) is $82.11 last updated November 5, 2026 at 5:23 PM EST.
There are no upcoming dividends for Zoetis.
Zoetis does not have any upcoming earnings scheduled.
There is no upcoming split for Zoetis.
Zoetis is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal...